drug · antibody
rituximab biosimilar
pre_registrationupdated 6mo agoby Dr. Reddy's Laboratories Ltd🔗 ChEMBL
community read0 votes
Antibody drug with a maximum clinical stage of Approval (across all indications), with 10 approved and 114 investigational indications.
indications
indications
DLBCLRheumatoid Arthritis
targets
B-lymphocyte antigen CD20
all catalysts(0)
nothing on the calendar yet
Trials studying rituximab biosimilar
- phase3A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- phase3A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
- phase2A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- phase3A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)
- phase2A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma
- phase2A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)
- phase3Compare Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB Follicular Lymphoma
News(8)
- Could we see 10 Chinese Big Pharmas within a decade? Some CEOs think soFor executives at many of the Chinese drug developers who spoke to Fierce, the real prize is a seat at the Big Pharma table. In recent years, this objective has moved from a vague aspiration to a c…fiercebiotech · 10d ago
- Celltrion picks up another Kaigene autoimmune antibody for up to $580.5MCelltrion has licensed a preclinical antibody targeting autoimmune conditions from Maryland-based biotech Kaigene in a deal worth up to $580.5 million, marking another step in the South Korean drug…fiercebiotech · 26d ago
- Epkinly data only one of Genmab's make-or-break readouts ahead of steep sales erosionBracing for patent losses on its cornerstone product Darzalex, Genmab has bet its future on three cancer programs that will deliver pivotal readouts in quick succession.biospace · 28d ago
- ‘We’re so close to the tech companies’: Genentech CEO talks Fierce through vision for the futureWhen recombinant DNA pioneer Herbert Boyer, Ph.D., first got a call from venture capitalist Robert Swanson about starting a company, the savvy scientist wasn’t sure a meeting would be worth his time.fiercebiotech · 1mo ago
- China’s Henlius carves out $440M T-cell engager deal with AmberstoneFosun Pharma subsidiary Henlius Biotech has signed a $440 million biobucks deal with California-based Amberstone Biosciences to work on T-cell engagers.fiercebiotech · 1mo ago
- Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drugUltragenyx’s second gene therapy approval since August gives it another sellable voucher. Elsewhere, Roche declared success in a blood cancer trial and a cell therapy maker is cutting costs.biopharma_dive · 1mo ago
- Ipsen’s $450M blood cancer drug; FDA selects first cohort for “pre-check” pilot programThe planned acquisition of Kartos Therapeutics would hand Ipsen a late-stage asset for myelofibrosis. Elsewhere, Sobi hit a regulatory setback and BeOne unveiled more positive Brukinsa data.biopharma_dive · 4mo ago
- A Spanish biotech banks $87M to make differentiated ADCsOna Therapeutics, a Barcelona-based drugmaker, is developing next-generation drugs it says could help patients with advanced forms of breast and colorectal cancers.biopharma_dive · 5mo ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that